Influence of CD26/dipeptidyl peptidase IV deficiency on immunophenotypic changes during colitis development and resolution
No, but you can react negatively to other ingredients in supplements
According to the new FDA labeling released in October 2025, providers should include pharmacogenomic testing (PGx) before beginning treatment with the chemotherapy drug capecitabine: Oncologists need to adapt their workflows to assess the risks posed by this warning label
[DOI] [PMC free article] [PubMed] [Google Scholar] Guo H., Li J., Hu H., Qin L., Chen L., Hao Q., Yang C., Wu R., Feng J., Liu R., Chen D., Li W., Hao S., Wang X
I dont know the answer to the first part, but the second part seems unlikely